Good Life Advisors LLC Sells 256 Shares of Eli Lilly and Company (NYSE:LLY)

Good Life Advisors LLC lessened its stake in shares of Eli Lilly and Company (NYSE:LLY) by 8.6% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,717 shares of the company’s stock after selling 256 shares during the period. Good Life Advisors LLC’s holdings in Eli Lilly and Company were worth $2,097,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Financial Perspectives Inc increased its position in shares of Eli Lilly and Company by 14.9% during the 4th quarter. Financial Perspectives Inc now owns 417 shares of the company’s stock worth $322,000 after purchasing an additional 54 shares during the last quarter. Pegasus Asset Management Inc. grew its stake in shares of Eli Lilly and Company by 79.2% in the fourth quarter. Pegasus Asset Management Inc. now owns 5,104 shares of the company’s stock valued at $3,940,000 after buying an additional 2,256 shares in the last quarter. Laidlaw Wealth Management LLC increased its holdings in Eli Lilly and Company by 8.6% during the fourth quarter. Laidlaw Wealth Management LLC now owns 1,878 shares of the company’s stock worth $1,450,000 after buying an additional 149 shares during the last quarter. Lyell Wealth Management LP increased its holdings in Eli Lilly and Company by 2.1% during the fourth quarter. Lyell Wealth Management LP now owns 2,532 shares of the company’s stock worth $1,955,000 after buying an additional 51 shares during the last quarter. Finally, Joel Adams & Associates Inc. acquired a new stake in Eli Lilly and Company in the fourth quarter valued at $926,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

LLY has been the topic of several recent analyst reports. Wolfe Research assumed coverage on shares of Eli Lilly and Company in a research note on Friday, November 15th. They set an “outperform” rating and a $1,000.00 price objective on the stock. Deutsche Bank Aktiengesellschaft dropped their price objective on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a research note on Monday, November 4th. Truist Financial raised their price objective on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a research report on Monday, February 3rd. Redburn Atlantic upgraded Eli Lilly and Company to a “hold” rating in a research note on Monday, November 4th. Finally, Citigroup reduced their price objective on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. Four investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $997.50.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $866.69 on Thursday. The business has a fifty day moving average price of $797.80 and a two-hundred day moving average price of $845.87. The stock has a market capitalization of $822.77 billion, a PE ratio of 74.01, a P/E/G ratio of 1.35 and a beta of 0.42. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. Eli Lilly and Company has a fifty-two week low of $711.40 and a fifty-two week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 86.26%. As a group, equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company declared that its Board of Directors has initiated a share repurchase plan on Monday, December 9th that permits the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization permits the company to repurchase up to 2% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s board of directors believes its stock is undervalued.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be given a $1.50 dividend. The ex-dividend date of this dividend is Friday, February 14th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 annualized dividend and a dividend yield of 0.69%. Eli Lilly and Company’s payout ratio is presently 51.24%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.